News

DOACs Associated With High Bleeding Rates, VTEs, ATEs in MPNs

11/09/2021

Novel clinical data from a multicenter retrospective analysis evaluates the safety of direct oral anticoagulant efficacy in patients with MPNs; these findings were presented at the 2021 Annual ASH Meeting.

Novel clinical data from a...

11/09/2021

Oncology

News

JAKi Therapy Yields Safe and Effective Results in Portal Hypertensive MPNs

11/08/2021

Results from an observational study were presented at the 2021 Annual ASH Meeting to demonstrate JAKi therapy as safe and effective in portal hypertensive patients with MPNs.

Results from an observational...

11/08/2021

Oncology

News

ASXL1 Mutation Identified as High-Risk Bleeding Factor in MPN

11/08/2021

Findings from a retrospective analysis were shared at the 2021 Annual ASH Meeting on novel bleeding risk factors in MPNs that can prevent surgical complications when identified, including the ASXL1 mutation.

Findings from a retrospective...

11/08/2021

Oncology

News

Triplet Combo Effective Conditioning Regimen for Patients With AML, MDS, or MPNs

10/28/2021

A study on treosulfan, fludarabine, and cytarabine found the combination provided tolerable, feasible, and effective conditioning for patients with AML, MDS, or MPNs.

A study on treosulfan,...

10/28/2021

Oncology

News

Quizartinib-Based Combos Improve Outcomes in AML, MDS

10/08/2021

Phase 1/2 study findings demonstrate the clinical efficacy of quizartinib plus azacitidine or low-dose cytarabine for the treatment of patients with AML or MDS.

Phase 1/2 study findings...

10/08/2021

Oncology

News

Venetoclax Plus Chemotherapy Improves OS in Patients With AML, MDS

08/23/2021

Findings from thee Phase 2 CLIA study shows the safety and activity of venetoclax plus chemotherapy in AML or MDS.

Findings from thee Phase 2 CLIA...

08/23/2021

Oncology

News

First-Line Fedratinib Improves PFS in Patients With MF

08/04/2021

Study findings suggest that first-line fedratinib significantly improves PFS compared with placebo in patients with MF.

Study findings suggest that...

08/04/2021

Oncology

Conference Insider

Venetoclax–Azacitidine Improves OS Over Azacitidine Alone in Treatment-Naïve Patients With tMN, A-MDS/MPNs

06/23/2021

Hina M. Porcelli ;

According to data presented at ASCO 2021, venetoclax plus azacitidine improved survival over azacitidine alone in treatment-naïve patients with tMN and antecedent MDS or MPNs.

According to data presented at...

06/23/2021

Oncology

News

Azacitidine Improves RBC-TI Rates in Patients with Lower-Risk MDS

04/23/2021

Oral azacitidine significantly improved RBC-TI rates and induced durable bilineage improvements in patients with lower-risk MDS and high-risk disease features, according to a phase 3 trial.

Oral azacitidine significantly...

04/23/2021

Oncology

News

Decitabine With or Without Ruxolitinib Shows Benefit in Advanced Phases of MPN

03/29/2021

When initiated early in the course of the disease, decitabine with or without ruxolitinib has shown clinical benefit in patients with advanced phases of MPNs.

When initiated early in the...

03/29/2021

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology